Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Selectis Health (GBCS) Gains from Sales and Divestitures (2020)

Selectis Health's Gains from Sales and Divestitures history spans 1 years, with the latest figure at $7500.0 for Q4 2020.

Quarterly results put Gains from Sales and Divestitures at $7500.0 for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was $7500.0 (changed N/A YoY), and the annual figure for FY2020 was $7500.0, changed.
Gains from Sales and Divestitures for Q4 2020 was $7500.0 at Selectis Health.
In the past five years, Gains from Sales and Divestitures ranged from a high of $7500.0 in Q4 2020 to a low of $7500.0 in Q4 2020.